Key Highlights
- Pfizer deepens its immuno-oncology pipeline through a $1.25B licensing agreement with 3SBio for SSGJ-707, a bispecific antibody in Phase II clinical trials.
- The antibody targets PD-1 and VEGF pathways, showing promise as a monotherapy for advanced NSCLC.
- Pfizer to lead global development, manufacturing, and commercialization, with potential expansion into the Chinese market.
A Bold Bet on Bispecifics
In a significant expansion of its oncology pipeline, Pfizer has obtained exclusive global rights to develop and commercialize SSGJ-707, a bispecific antibody that simultaneously targets PD-1 and VEGF. Developed by China-based 3SBio, the antibody is being studied as a treatment for several solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, and gynecological malignancies.
Under the agreement, Pfizer will pay $1.25 billion upfront, including a $100 million equity investment in 3SBio. The deal also includes a $150 million option payment if Pfizer elects to expand rights to China.
Clinical Promise in NSCLC
Interim results from a Phase II clinical trial presented at the 2025 ASCO Annual Meeting showed SSGJ-707 has favorable safety and efficacy as a monotherapy in patients with advanced NSCLC. Pfizer plans to initiate Phase III trials with global sites, prioritizing NSCLC and other solid tumors as lead indications. Manufacturing will be conducted at Pfizer’s U.S. facilities in Sanford, NC (drug substance) and McPherson, KS (drug product).
“This agreement highlights our strategic focus on next-generation oncology biologics,” said Dr. Chris Boshoff, Chief Scientific Officer at Pfizer. “SSGJ-707 adds a promising dual-targeted candidate to our immunotherapy platform, aligning with our efforts to deliver innovative cancer treatments.”
Pipeline Momentum
The deal bolsters Pfizer’s portfolio of bispecific antibodies and comes shortly after the company announced positive Phase III results for its prostate cancer therapy XTANDI in high-risk biochemical recurrence settings (source).
About Pfizer
Pfizer Inc. is a global biopharmaceutical company committed to applying science and global resources to deliver breakthroughs that change patients’ lives. Pfizer’s Oncology division is advancing a robust pipeline of targeted therapies, biologics, and next-gen immuno-oncology drugs, with a focus on breast, thoracic, genitourinary, and hematologic cancers.
About 3SBio
3SBio is a leading China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biologics. With a strong pipeline and global partnerships, 3SBio specializes in treatments for oncology, autoimmune, and other chronic conditions.
By
